Duloxetine (Cymbalta) News, Updated Regularly

Lilly sues generic drugmakers to protect Cymbalta - WTHR
November 18, 2008, 2:50 pm

Indianapolis - Eli Lilly and Co. has filed a federal suit against four generic drugmakers to protect its patent for the antidepressant drug Cymbalta. The Indianapolis company sued Cobalt Laboratories, Impax Laboratories, Sandoz and Wockhardt Ltd ...

Duloxetine: a review of safety reports - Xagena Medical News
November 12, 2008, 11:25 pm

Duloxetine ( Cymbalta ) is a serotonin and norepinephrine reuptake inhibitor ( SNRI ) for oral administration initially approved in August 2004 to treat major depressive disorder. Subsequently, FDA approved Duloxetine for the treatment of diabetic ...

Little-known provision in financial bailout package could provide some ... - MLive.com
November 13, 2008, 6:49 am

Ryan Garza | The Flint Journal "It'd be months I'd be cooped up in the house laying on this couch sick. Depression is a mental illness," said Dallas Koontz, of Flushing, while taking a break from folding clothes at his home. Koontz has battled ...

Lilly Sues Four Generic Drugmakers To Protect Patents Covering ... - TradingMarkets.com
November 18, 2008, 7:36 pm

Lilly sued Cobalt Laboratories Inc., Impax Laboratories Inc., Sandoz Inc. and Wockhardt Ltd. The company filed the lawsuit after the companies filed abbreviated new drug applications to make and sell duloxetine hydrochloride capsules before Lilly's ...

GE shrinks loan unit, to cut jobs - Fort Wayne Journal Gazette
November 19, 2008, 2:53 am

General Electric Co. said Tuesday that it is reorganizing its GE Capital unit to save $2 billion next year, a move the company said will lead to job cuts as it restructures and shrinks the size of the lending arm battered by the credit crisis. In a ...

Lilly Sues Generic Drugmakers to Protect Cymbalta - WIBC.com
November 18, 2008, 1:45 pm

Drugmaker Eli Lilly and Co. is suing four generic drugmakers to protect patents covering its second-best selling drug, the antidepressant Cymbalta. Lilly sued Cobalt Laboratories Inc., Impax Laboratories Inc., Sandoz Inc. and Wockhardt Ltd. Friday in ...

Eli Lilly sues Impax Laboratories - East Bay Business Times
November 18, 2008, 1:09 pm

Eli Lilly & Co. sued generic drug maker Impax Laboratories Inc. for patent infringement. The suit deals with an Impax copy of the Eli Lilly (NYSE: LLY) drug Cymbalta, an antidepressant. In addition to Hayward-based Impax, Lilly also sued Cobalt ...

2nd Generation Antidepressants Prove Effective - National Womens Health Information Center
November 18, 2008, 7:47 am

TUESDAY, Nov. 18 (HealthDay News) -- Second generation antidepressants are all equally effective, according to a new clinical practice guideline released by the American College of Physicians. The guideline authors reviewed more than 200 published ...

Newer antidepressants are equally effective - Los Angeles Times Blogs
November 17, 2008, 2:22 pm

Second-generation antidepressants, such as Prozac, Paxil, Zoloft and nine other medications, are equally effective, according to guidelines issued today by the American College of Physicians. Since the medications work equally well, doctors and ...

ACP Guideline Finds No Substantial Differences Among â??Second ... - PR Inside
November 17, 2008, 5:21 pm

No substantial differences in efficacy or quality of life were found among "second-generation" antidepressants used to treat depressive disorders such as major depressive disorder, according to a new clinical practice guideline from the American ...

Are you looking for additional Cymbalta (Duloxetine) news? Try our new "Duloxetine News Focus" area.

Are you looking for additional Cymbalta (Duloxetine) information? Try our new "Duloxetine Related Blog Entries" area.

Off-site Duloxetine (Cymbalta) Links, User Submitted

The following links have been collected through user bookmark submission in the Duloxetine_Cymbalta category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Fri Oct 24

• Duloxetine - Wikipedia, the free encyclopedia

Tue Jul 29

• duloxetine medical facts from Drugs.com

Fri May 16

• Treating the physical symptoms of depression with second-generat ion antidepressant s: a systematic review and metaanalysis: The authors found insufficient evidence to support the choice of one second-generat ion antidepressant over another in patients with pain accompanying depression.

Sat Mar 29

• Duloxetine - Wikipedia, the free encyclopedia

Sat Jan 5

• Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.: These results support duloxetine 9;s efficacy and tolerability in the treatment of pain and depression in patients with at least moderate pain associated with depression.

Fri Jan 4

• A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.: These data imply that starting dulox-etine at 30 mg q.a.m. for 1 week with or without food or starting duloxetine at the therapeutic dose of 60 mg q.a.m. with food can improve the initial tolerability of the medication.

Sun Oct 14

• Cymbalta (duloxetine HCl): Dual Reuptake Inhibitor In Action

Thu Sep 13

• Duloxetine associated with smoking cessation -- Marcil and Petty 39 (9): 1578 -- The Annals of Pharmacotherap y

Mon Aug 20

• Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Contro lled Trial -- Raskin et al. 164 (6): 900 -- Am J Psychiatry: Duloxetine improved cognition, depression, and some pain measures and was safe and well tolerated in elderly patients with recurrent major depressive disorder.

Sun Dec 24

• Depression

Mon Oct 2

• Cymbalta Antidepressant Benefits: CYMBALTA dual uptake inhibitors

Off-site Duloxetine Research Links

If you still need additional information on Duloxetine then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.